指南与共识消化系统肿瘤

II期结肠癌辅助治疗:ASCO指南更新

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2021-12-22

ASCO召集专家小组系统综述相关研究,制定II期结肠癌术后辅助治疗推荐。指南明确非高危亚组不常规推荐辅助化疗,T4肿瘤应提供辅助化疗,其他高危因素可提供辅助化疗;错配修复缺陷/微卫星不稳定肿瘤不常规提供辅助化疗;含奥沙利铂方案疗程3或6个月,决策依据5年无病生存证据与不良事件率。

要点

  • 非高危亚组II期结肠癌不常规推荐辅助化疗。
  • T4肿瘤应提供辅助化疗;其他高危因素可提供辅助化疗。
  • 错配修复缺陷/微卫星不稳定肿瘤不常规提供辅助化疗。

核心结论

  • 非高危亚组II期结肠癌不常规推荐辅助化疗;T4肿瘤应提供辅助化疗;其他高危因素可提供辅助化疗;错配修复缺陷/微卫星不稳定肿瘤不常规提供辅助化疗。

研究设计与样本

  • ASCO召集专家小组对相关研究进行系统综述并制定临床实践推荐;21项观察性研究和6项随机对照试验符合系统综述纳入标准。

主要发现

  • T4肿瘤复发风险较高,应提供辅助化疗。
  • 高危因素包括手术标本淋巴结采样少于12枚、神经侵犯或脉管侵犯、低分化或未分化肿瘤分级、肠梗阻、肿瘤穿孔或BD3级肿瘤出芽,可提供辅助化疗。
  • 氟嘧啶类辅助化疗基础上加用奥沙利铂不常规推荐,但可在共同决策后提供。
  • 错配修复缺陷/微卫星不稳定肿瘤不常规提供辅助化疗;若合并高危因素决定提供辅助化疗,推荐含奥沙利铂化疗。

关键数值与推荐

  • 非高危亚组II期结肠癌不常规推荐辅助化疗。
  • T4肿瘤应提供辅助化疗。
  • 其他高危因素可提供辅助化疗。
  • 含奥沙利铂方案不常规推荐,但可在共同决策后提供。
  • 错配修复缺陷/微卫星不稳定肿瘤不常规提供辅助化疗;若决定提供辅助化疗,推荐含奥沙利铂化疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria. RECOMMENDATIONS: Adjuvant chemotherapy (ACT) is not routinely recommended for patients with stage II colon cancer who are not in a high-risk subgroup. Patients with T4 tumors are at higher risk of recurrence and should be offered ACT, whereas patients with other high-risk factors, including sampling of fewer than 12 lymph nodes in the surgical specimen, perineural or lymphovascular invasion, poorly or undifferentiated tumor grade, intestinal obstruction, tumor perforation, or grade BD3 tumor budding, may be offered ACT. The addition of oxaliplatin to fluoropyrimidine-based ACT is not routinely recommended, but may be offered as a result of shared decision making. Patients with mismatch repair deficiency/microsatellite instability tumors should not be routinely offered ACT; if the combination of mismatch repair deficiency/microsatellite instability and high-risk factors results in a decision to offer ACT, oxaliplatin-containing chemotherapy is recommended. Duration of oxaliplatin-containing chemotherapy is also addressed, with recommendations for 3 or 6 months of treatment with capecitabine and oxaliplatin or fluorouracil, leucovorin, and oxaliplatin, with decision making informed by key evidence of 5-year disease-free survival in each treatment subgroup and the rate of adverse events, including peripheral neuropathy.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2021. PMID: 34936379. doi:10.1200/JCO.21.02538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。